1.. Introduction {#S1}
================

DNA methylations occur at cytosine which might affect the modifications of DNA molecules. In this process, the gene expressions can be regulated without changing the DNA sequences. In particular, the related gene silencing of DNA methylations is a well-accepted epigenetic mechanism that often occurs at tumor suppressor genes loci in human cancers \[[@ref001], [@ref002], [@ref003], [@ref004], [@ref005]\]. Recently, some high-throughput DNA methylation platforms have generated amounts of DNA methylation data and mostly based on genotyping bisulfite converted DNA. In this paper, one of the popular platforms, Illumina Infinium HumanMethylation 27K array, was used. Additionally, the $\beta$-values indicate the methylation status of the CpG sites within the array while each site's value is calculated by the average of approximately 30 replicates \[[@ref006]\]. Every individual $\beta$-value is a continuous variable between 0 and 1, where zero means unmethylated and one means methylated.

To date, researchers have selected methylated sites by statistical classification approaches \[[@ref007], [@ref008], [@ref009]\]. Even though most of the CpG sites display various degrees of methylation, only a few gene expressions change. The statistical approaches therefore are difficult to find relevant CpG sites from high-dimensional data, making the statistical approaches not suitable for methylation data. In order to select CpG sites, different parameter models were utilized by researchers to represent diverse status of the samples \[[@ref010]\]. Methylation data expresses different features from gene expression data. Firstly, the DNA methylation data has a group effect feature among CpG sites based on gene groups and CpG island groups. Secondly, the DNA methylation data values range between 0 and 1. Based on these features, Sun \[[@ref011]\] has proposed a procedure that merged the $L_{1}$ penalty and squared $L_{2}$ penalty to select methylated CpG sites.

With the Illumina HumanMethylation 27K array, each gene has about 1--25 correlated CpG sites and each CpG island has about 2--11 CpG sites. Based on these aspects of DNA methylation data, a $L_{1/2}$ penalized logistic regression model has been introduced to select potentially diseased pathogenic CpG sites within one gene. The $L_{1/2}$ regularization can be represented by $L_{q}$ (0 $< q <$ 1) regularization and has exhibited properties for instance unbiasedness, sparsity and oracle \[[@ref012]\]. Additionally, the sparsity of the $L_{1/2}$ regularization is better than $L_{1}$ regularization \[[@ref012], [@ref013], [@ref014]\]. Based on the $L_{1/2}$ penalized logistic regression model, we used the proposed network structure (the central node fully connected network) to describe the two correlated CpG sites' patterns, one is based on the gene group, whilst the other is based on the CpG island group. The proposed method is designed to select CpG sites by group effect that associate with diseases. The aimed method has a finer specificity than present methods, as it for instance has the potential to select more relevant genes.

2.. Methods {#S2}
===========

2.1. Network-regularization {#S2.SS1}
---------------------------

In this research, $n$ samples were used, $D = {\{{(X_{1},y_{1})},{(X_{2},y_{2})},\ldots,{(X_{n},y_{n})}}$ where $X_{i} = {(x_{i1},x_{i2},\ldots,x_{ip})}$ is the methylation $\beta$-*value* of the $i$-th sample and $p$ represents the total number of CpG sites, the dependent variable $y_{i}$ is a binary variable where 0 implies controls and 1 implies cases. The logistic regression is:

$${f\left( x_{i},\varphi \right)} = \frac{\text{𝑒𝑥𝑝}\left( {x_{i}^{T}\varphi} \right)}{1 + {\text{𝑒𝑥𝑝}\left( {x_{i}^{T}\varphi} \right)}}$$

where $\varphi$ is the regression coefficients. The logistic log-likelihood is defined as:

$${l\left( \varphi \right)} = {- {n^{- 1}{\sum\limits_{i = 1}^{n}{\lbrack{{y_{i}\text{𝑙𝑜𝑔𝑓}\left( x_{i},\varphi \right)} + {{({1 - y_{i}})}\text{𝑙𝑜𝑔}{({1 - {f{(x_{i},\varphi)}}})}}}\rbrack}}}}$$

$\varphi$ was obtained by minimizing the log-likelihood. In high dimensional application, it is not appropriate to solve the logistic model directly and may result in overfitting. Hence, the regularization approaches are employed to aim at the overfitting problem. The sparse logistic regression can be laid out as Eq. ([2](#S2.E2)) when a regularization term is added:

$$\varphi^{*} = {\text{𝑎𝑣𝑔𝑚𝑖𝑛}{({{- {l\left( \varphi \right)}} + {P{(\varphi)}}})}}$$

where $P{(\varphi)}$ is the penalty function.

Lasso ($L_{1}$) and $L_{2}$, a well-recognized regularization approach was used in previous methods. The $L_{2}$ does not have sparsity and $L_{1}$ has a sparsity less than $L_{q}$ (0 $< q <$ 1). Nonetheless, when $q$ lies closer to zero, results show a sparser $L_{q}$ and subsequently more challenging to converge. Therefore, some researchers \[[@ref012]\] investigated the properties of $L_{q}$ (0 $< q <$ 1) regularization and demonstrated the $L_{1/2}$ regularization is particularly essential and crucial. The performance between $L_{q}$ penalty and $L_{1/2}$ has no significant diversity whereas the $L_{1/2}$ regularization is much more facile to solve. Accordingly, the $L_{1/2}$ regularization can be laid out as $L_{q}$ (0 $< q <$ 1) regularization which exhibits unbiasedness as well as oracle properties \[[@ref012], [@ref013], [@ref014]\]. In high-dimensional DNA methylation data, disease-related CpG sites are very limited and therefore, in practice, the $L_{1/2}$ penalty methodology would be more significant than the $L_{0}$, $L_{1}$ and $L_{2}$ approaches. Consequently, the $L_{1/2}$ penalty was favored in our logistic regression model.

Some methods have been provided in order to tackle highly correlated variables. *Elastic net* penalty ($L_{1} + L_{2}$) and *HLR* ($L_{1/2} + L_{2}$) emphasizes a grouping effect and tend to smooth the coefficient profiles. However, the pathway information was neglected in these methods. To merge CpG sites deduction into the analysis of high-demensional methylation data, we extended a network-based regularization technique designed for the $L_{1/2}$ penalty.

The methylation data displays a strong group effect and thus previous research used a fully connected network (Fc.net) to describe the correlated CpG sites group patterns within a gene. In methylation data, the group effect of CpG sites is not only present within one gene and present within one CpG island. There are overlapping parts between groups and these overlapping parts correlate with both parts respectively. With the different previous network, we set the overlapping part as the central node and connect it with other correlated parts (Fig. [1](#thc-28-thc209016-g001){ref-type="fig"}). The network not only has the genome information or CpG island information, but also the two aspects of information integrated into the network. It can better reflect the relevance of CpG site.

Figure 1.a. Previous fully connected network. b. Central node fully connected network.

The network information is represented in a graphed structure with p-dimensional Laplacian matrix $L = {\{ l_{ab}\}}$. It is defined as:

$$l_{\text{𝑎𝑏}}^{*} = \left\{ \begin{array}{ll}
1 & {{\text{𝑖𝑓}a} = {b\text{𝑎𝑛𝑑}d_{a}} \neq 0} \\
{- {({d_{a}d_{b}})}^{- {1/2}}} & \textit{if\ a\ and\ b\ are\ linked\ with\ each\ other} \\
0 & \text{𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒} \\
\end{array} \right.$$

where $d_{a}$ is the total number of connections at vertex $a$ in graph.

The penalty function in Eq. ([3](#S2.E3)) is:

$${P\left( \varphi \right)} = {{\lambda_{1}\left. ||\varphi \right.||^{- \frac{1}{2}}} + {\lambda_{2}\varphi^{T}L\varphi}} = {{\lambda_{1}{\sum\limits_{i = 1}^{p}\left| \varphi_{i} \right|^{- \frac{1}{2}}}} + {\lambda_{2}{\sum\limits_{a = 1}^{p}{\sum\limits_{a \sim b}\left( {\frac{\varphi_{a}}{\sqrt{d_{a}}} - \frac{\varphi_{b}}{\sqrt{d_{b}}}} \right)}}}}$$

where $|| \cdot ||^{1/2}$ is a $L_{1/2}$ norm and $a \sim b$ illustrate the variables which are linked to the *a-th* predictor. The sparsity and smoothness are controlled by the parameters $\lambda_{1}$ and $\lambda_{2}$.

The effectiveness of the penalty function reduced significantly when two negatively correlated predictors are interacted; the signs of coefficients are thus predicted and added to the Laplacian matrix to overcome problem:

$$l_{ab}^{*} = \left\{ \begin{array}{ll}
1 & {{\text{𝑖𝑓}a} = {b\text{𝑎𝑛𝑑}d_{a}} \neq 0} \\
{- {\text{𝑠𝑔𝑛}{(\varphi_{a}^{*})}\text{𝑠𝑔𝑛}{(\varphi_{b}^{*})}{({d_{a}d_{b}})}^{- {1/2}}}} & \textit{if\ a\ and\ b\ are\ linked\ with\ each\ other} \\
0 & \text{𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒} \\
\end{array} \right.$$

The adaptive net function can be written as:

$${\varphi^{T}L^{*}\varphi} = {\sum\limits_{a = 1}^{p}{\sum\limits_{a \sim b}\left( {\frac{\text{𝑠𝑔𝑛}{(\varphi_{a}^{*})}\varphi_{a}}{\sqrt{d_{a}}} - \frac{\text{𝑠𝑔𝑛}{(\varphi_{b}^{*})}\varphi_{b}}{\sqrt{d_{b}}}} \right)^{2}}}$$

Based on $\left| \beta_{a} \right| \approx {\text{𝑠𝑔𝑛}{(\beta_{a}^{*})}\beta_{a}}$ for $\beta_{a} \approx \beta_{a}^{*}$, the adaptive penalty function can be written as:

$${P\left( \varphi \right)} = {{\lambda_{1}{\sum\limits_{j = 1}^{p}\left| \varphi_{j} \right|^{1/2}}} + {\lambda_{2}{\sum\limits_{a = 1}^{p}{\sum\limits_{a \sim b}\left( {\frac{\left| \varphi_{a} \right|}{\sqrt{d_{a}}} - \frac{\left| \varphi_{b} \right|}{\sqrt{d_{b}}}} \right)^{2}}}}}$$

2.2. The coordinate descent algorithm {#S2.SS2}
-------------------------------------

To solve regularization models, the coordinate descent algorithm adopted as a competent tool. Regarding the coordinate descent algorithm, we referred to previous research \[[@ref015], [@ref016], [@ref011]\] and Eq. ([2](#S2.E2)) can be linearized by Taylor series expansion at current estimates $\varphi^{*}$:

$${l^{*}\left( \varphi \right)} \approx {\frac{1}{2}n^{- 1}{\sum\limits_{i = 1}^{n}{w_{i}\left( {z_{i} - {x_{i}^{T}\varphi}} \right)^{2}}}}$$

where $z_{i} = {{x_{i}^{T}\varphi^{*}} + {{({y_{i} - {f^{*}{(x_{i})}}})}/w_{i}}}$, $w_{i} = {f^{*}{(x_{i})}{({1 - {f^{*}{(x_{i})}}})}}$, ${f^{*}\left( x_{i} \right)} = {{\text{𝑒𝑥𝑝}\left( {x_{i}^{T}\varphi^{*}} \right)}/{({1 + {\text{𝑒𝑥𝑝}{({x_{i}^{T}\varphi^{*}})}}})}}$.

Next, the estimator:

$$\varphi_{a}^{*} = \frac{s{({{n^{- 1}{\sum_{i = 1}^{n}{w_{i}x_{ia}\left( {z_{i} - {\overset{\sim}{z}}_{i}^{(a)}} \right)}}} + {\lambda_{2}g\left( a \right)}},\lambda_{1})}}{\lambda_{2} + 1}$$

where ${\overset{\sim}{z}}_{i}^{(a)} = {\sum_{j \neq i}{x_{ij}\varphi_{j}^{*}}}$, ${g\left( a \right)} = {\sum_{a \sim b}\frac{\left| \varphi_{b}^{*} \right|}{\sqrt{d_{a}d_{b}}}}$ and $s{(\sigma,\gamma)}$ is an enhanced $L_{1/2}$ thresholding operator for the coordinate descent algorithm \[[@ref012], [@ref013], [@ref014]\].

$${S\left( \sigma,\gamma \right)} = \left\{ \begin{array}{ll}
{\frac{2}{3}\sigma\left( {1 + {\text{𝑐𝑜𝑠}\left( \frac{2{({\pi - {\phi_{\gamma}{(\sigma)}}})}}{3} \right)}} \right)} & {{\text{𝑖𝑓}\left| \sigma \right|} > {\frac{\sqrt[3]{54}}{4}{(\gamma)}^{\frac{2}{3}}}} \\
0 & \text{𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒} \\
\end{array} \right.$$

where ${\phi_{\gamma}\left( \sigma \right)} = {\text{𝑎𝑐𝑟𝑜𝑠𝑠}{({{({\gamma/8})}{({{|\sigma|}/3})}^{2/3}})}}$.

3.. Results and discussion {#S3}
==========================

3.1. Analyses of simulated data {#S3.SS1}
-------------------------------

The performance of the proposed simulation study quoting the simulation from Teschendorff et al. \[[@ref017]\] and Su and Wang \[[@ref011]\] was analyzed and evaluated. There were 600 groups, which were divided into 100 groups, 150 groups and 7 sets of 50 groups in accordance to their number of CpG sites. Each group comprised of at least 1 CpG site up to 9 CpG sites reciprocally. In total, there were 2500 CpG sites.

First, we simulated variables with the group effect ranging between 0 and 1. So we performed an inverse logit transformation on a multivariate normal distribution variable to represent the $\beta$-*values* of the *i-th* CpG site in the *g-th* group.

$$x_{i,g} = {\frac{\text{exp}\left( t_{i,g} \right)}{1 + {\text{exp}\left( t_{i,g} \right)}},t_{{i,g} \sim {2N_{s_{g}}{(\mu,\sigma)}}}}$$

where $s_{g}$ is the size of group, i.e. $1 \leqslant s_{g} \leqslant 9$. In this simulation model, we set $\mu = {({- 1},\ldots,{- 1})}^{T}$, $x_{i,g}$ ranging between 0 (unmethylated) to 1 (completely methylated). The relationship of CpG sites within group is shown by $\sigma$. The covariance matrix $\sigma$ is presented as follows:

(1)$\sigma = \rho^{|{a - b}|},\rho =$ 0.2, 0.5, 0.7.(2)$\sigma = \rho$ for a $\neq$ b and and $\sigma =$1 for $a = b$, $\rho =$ 0.2, 0.5, 0.7.

The first condition is autoregressive (AR) model, and the second condition is compound symmetric correlation model. We set three different correlation coefficients $\rho =$ 0.2, 0.5 and 0.7 for all conditions \[[@ref018], [@ref019]\].

Second, given the regression coefficients $\varphi$ based on previous research, $\varphi_{g} = {(\varphi_{1,g},\ldots,\varphi_{p_{g},g})}^{T}$ is the coefficient of CpG sites within the *g-th* group. After that, one group from each of the 9 different groups was selected to set the regression coefficients. At this step, there were 45 CpG sites which have been assigned the regression coefficients value. The regression coefficients $\varphi_{k,g}$ are presented as:

$$$$

when $\delta$ is the strength of the true signals. The other sets of regression coefficients were set to 0.

In the simulation models, there were 45 pathogenic CpG sites in a total of 2500 CpG sites. Lastly, the $y_{i}$ is given by Bernoulli distribution. For each simulation set, there were 200 cases and 200 controls. There were nine simulation conditions based on different parameters, for instance the strength of the true signals.

Table 1The total area under the averaged ROC curves (AUC) and MSE for all models$\delta$$\sigma$$\rho$LassoEnet$L_{1} +$ *Fc.net*$L_{1/2}$*HLR* ($L_{1/2} + L_{2}$)$L_{1/2} +$ *Fc.net*AUCMSEAUCMSEAUCMSEAUCMSEAUCMSEAUCMSE1AR(1)0.20.8060.2730.8470.2380.8500.2390.8090.2600.8530.254**0.8600.197**1AR(1)0.50.8710.2130.8850.2060.8880.1970.8560.2250.9330.161**0.9540.116**1AR(1)0.70.8980.1870.9060.1850.9090.1750.9170.1690.9420.149**0.9620.101**2AR(1)0.20.8060.2730.8600.2370.8660.2200.8090.2600.8690.213**0.9210.155**2AR(1)0.50.8710.2730.8890.2370.9030.2200.9180.1670.9530.134**0.9750.085**2AR(1)0.70.8980.1870.9040.1770.9120.1680.9170.1690.9530.133**0.9700.089**2CS0.20.8520.2260.8790.2070.8890.1930.8200.2570.8930.197**0.9360.139**2CS0.50.8990.1810.9130.1630.9190.1570.8950.1820.9610.128**0.9690.097**2CS0.70.9240.1620.9270.1570.9340.1470.9150.1710.9570.125**0.9790.080**

Figure 2.The ROC curve of every model.

We repeated simulations 100 times for each condition. We then used the 10-fold cross-validation (CV) approach in the training set in order to tune the optimal regularization parameters of the *Lasso*, *Elastic-Net* (*Enet*), $L_{1} +$*Fc.net*, $L_{1/2}$, *HLR* ($L_{1/2} + L_{2}$), $L_{1/2} +$*Fc.net*. Note that, the *Enet*, $L_{1} +$*Fc.net*, *HLR* ($L_{1/2} + L_{2}$) and $L_{1/2} +$*Fc.net* methods have two-dimensional parameter surfaces in the 10-*CV* approach. Afterwards, the logistic regressions with the estimated tuning parameters were employed to build different classifiers. Lastly, the attained classifiers were adopted to the test set for further classification and prediction.

Table 2The AUC of real data for each methodLassoEnet$L_{1} +$ *Fc.net(gene)*$L_{1/2}$*HLR* ($L_{1/2} + L_{2}$)$L_{1/2} +$ *central node Fc.net*Pre0.7980.8860.9210.8030.9080.946Post0.7620.8980.9340.7710.9230.948

Figure 3.The histogram of correlation between CpG sites.

Figure [2](#thc-28-thc209016-g002){ref-type="fig"} shows the receiver operating characteristic curve (ROC curve) for every model. The green solid line ($L_{1/2} +$*Fc.net*) is closer to the upper left corner in the system than other line. So the effect of $L_{1/2} +$*Fc.net* is at optimal for the other algorithm in each model. Table [1](#T1){ref-type="table"} shows the total area under the averaged ROC curves and the MSE of every model respectively. From Table [1](#T1){ref-type="table"} it can be seen that $L_{1/2} +$*Fc.net* also has a very good performance within all models. In general, our proposed enhanced $L_{1/2}$ model achieved preponderant accuracy rates in all models in comparison to the other methods (the *Lasso*, *Enet*, $L_{1} +$*Fc.net*, $L_{1/2}$ and *HLR* ($L_{1/2} + L_{2}$)).

Table 3The top 20 CpG sites and the corresponding genes selected from the comparison between pre-treatment and normal control casesEnet$L_{1}$ $+$ *Fc.net (gene)HLR* ($L_{1/2} + L_{2}$)$L_{1/2}$ $+$ *central node Fc.net*cg1100973cg0237448**cg2079283**cg15616083cg02505409cg21493583**cg11804789**cg06409153(MARCO)(PRF1)**(PTPRCAP)**(PAGE2)(ANGPTL4)(CRIPT)**(CST7)**(ABCA5)**cg0498897**cg2007009**cg04988978**cg27303882cg06521852cg00201234cg24505527**cg05923103(MPO)**(S100A8)**(MPO)**(MYL4)(HRIHFB2122)(FBLN2)(NKIRAS2)**(RNF11)cg2079283**cg2706761cg0996492cg05294455cg08694544cg09638834**cg15853125**cg09497789**(PTPRCAP)**(CYP4F3)(KCNE1)(ADORA1)(RTBDN)(RAET1L)**(TIAM1)**(SPAG17)cg0996492cg0435376cg11009736cg13626881**cg15853125**cg14861570cg08694544cg13626881(KCNE1)(MS4A6A)(MARCO)(ADORA1)**(TIAM1)**(MMD)(RTBDN)(ADORA1)cg0652185cg0224062cg14360917**cg11412582**cg21608192cg09964921cg07607462**cg11412582**(HRIHFB2122)(PLCB2)(SP2)**(HOXB5)**(XYLT1)(KCNE1)(UBR1)**(HOXB5)**cg0013453cg0619637cg03801286cg01405107cg09497789**cg04988978cg20792833**cg15736165(UBASH3A)(TREM1)(KCNE1)(IGLL1)(SPAG17)**(MPO)(PTPRCAP)**(BNC1)cg1436091cg21126943cg06521852cg10494770**cg20792833**cg14319409**cg14027234cg05105069**(SP2)(CEACAM6)(HRIHFB2122)(SNRPN)**(PTPRCAP)**(GLRA1)**(CD248**)**(TCEAL7)**cg2193281cg0020123cg21517055cg24993443cg06409153cg26838900cg00201234cg07376232(CSTA)(FBLN2)(MGC11271)(BRDG1)(ABCA5)(LRRC15)(FBLN2)(AMICA1)cg0097486cg2746119cg00201234cg04398282cg13626881cg23490074**cg04988978**cg21493583(FCGR3B)(FXYD1)(FBLN2)(ABCA5)(ADORA1)(C19orf2)**(MPO)**(CRIPT)cg2151705cg0529445cg00134539**cg14027234**cg2193281cg17231524cg06183267**cg03856723**(MGC11271)(MYL4)(KCNQ2)**(CD248**)(CSTA)(MGC39606)(AFF3)**(PRKACA)**

Figure 4.The boxplot of correlation between CpG sites.

3.2. Analyses of real data {#S3.SS2}
--------------------------

To further evaluate the effectiveness of our proposed method, in this section, we examined the DNA methylation (ovarian cancer) data generated from Illumina Infiniumm HumanMethylation 27K Beadchip \[[@ref020]\]. The data is accessible from NCBI (<http://www.ncbi.nlm.nih.gov/>).

The data was generated by llumina Infiniumm HumanMethylation 27K Beadchip that contains 22727 CpG sites. We first removed samples which were low in BS conversion efficiency or low in CpG coverage. After that, a total of 207 genes contained more than 3 CpG sites and 295 CpG islands contained more than 3 CpG sites in the data; samples with error were removed. Lastly, there were 156 controls case samples (Healthy sample), 120 pre-treatment case samples and 122 post-treatment case samples. For these three cases, we calculated the maximum correlation of CpG sites in each group (gene and CpG island).

Figure [3](#thc-28-thc209016-g003){ref-type="fig"}a--c shows the histogram of maximum sample correlation between CpG sites within genes in control, pre-treatment and post-treatment case where Fig. [3](#thc-28-thc209016-g003){ref-type="fig"}d--f shows the histogram of maximum sample correlation between CpG sites within CpG islands in control, pre-treatment and post-treatment cases. Figure [4](#thc-28-thc209016-g004){ref-type="fig"} shows the boxplot of maximum sample correlation between CpG sites in gene or CpG islands. Based on Figs [3](#thc-28-thc209016-g003){ref-type="fig"} and [4](#thc-28-thc209016-g004){ref-type="fig"}, the results show that most CpG sites within the same group have high correlation in pre-treatment case samples and post-treatment case samples whereas the control case samples only show a significant correlation.

Table 4The top 20 CpG sites and the corresponding genes selected from the comparison between post-treatment and normal control casesEnet$L_{1}$ $+$ *Fc.net (gene)HLR* ($L_{1/2} + L_{2}$)$L_{1/2}$ $+$ *central node Fc.net*cg23580000cg09626634cg06653796cg12243271cg17682828cg25554036cg11093356cg04836428(ADCY7)(EBI2)(LIME1)(CFI)(FXYD7)(WFS1)(DDX19A)(DTNA)cg06653796cg22988566cg10986043cg10467098cg02713563cg23125689**cg12711814cg10777851**(LIME1)(WFDC10B)(TCAP)(Bles03)(TRAPPC6A)(CD81)**(ENO1)(CD200)**cg10986043cg24335895cg23580000cg19573166cg06653796**cg04232649**cg12906740cg00636639(TCAP)(COX7A1)(ADCY7)(SLC22A17)(LIME1)**(CCNG1)**(NUDT15)(MRRF)cg13379236cg19573166cg13379236cg15096140cg15489301cg25410053**cg14838256**cg17133388(EGF)(SLC22A17)(EGF)(MYO1B)(AKR1B10)(ZIC3)**(SRD5A2L)**(C3orf28)cg03547797cg15096140cg03547797cg05767404cg11093356cg24643262cg23002907cg14275779(GAS2)(MYO1B)(GAS2)(C1orf150)(DDX19A)(BMX)(RBMS2)(PLEKHH3)cg05135288cg13745870cg05135288cg05004940cg03547797cg26200585cg02964389cg07389922(RHOT2)(SPATA12)(RHOT2)(C20orf195)(GAS2)(PRX)(PSMD9)(C17orf81)cg20357806cg00134539cg12006284cg23506842cg20630655cg14132995**cg23917399**cg19514928(PPBP)(UBASH3A)(WT1)(PTPN7)(RNUT1)(SLC35A2)**(TNFAIP8)**(TMEM56)cg12006284cg16853982cg20357806cg23917399cg10986043cg13056210cg09119665cg05798972(WT1)(ACTN2)(PPBP)(SPATA12)(TCAP)(MXRA5)(PNMA1)(PPARBP)cg21640749cg10467098cg24335895cg09626634cg02497758cg04499381cg17682828cg00096922(CD300LF)(Bles03)(COX7A1)(EBI2)(MAFB)(CXorf9)(FXYD7)(DLX5)cg12243271cg13247990cg21640749**cg23917399**cg25919221cg13435792cg09816912cg04232649(CFI)(MLCK)(CD300LF)**(TNFAIP8)**(CA6)(C12orf46)(MARCKS)(**CCNG1**)

Table [2](#T2){ref-type="table"} shows the AUC for each method from real data analysis. In real data, the enhanced $L_{1/2}$ model also achieved higher accuracy rates. Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} show the top 20 selected CpG sites for all methods. We further validated the chosen genes from the GeneCards Database (<http://www.genecards.org>). In Table [3](#T3){ref-type="table"}, when comparing pre-treatment cases with controls, the algorithm $L_{1/2} +$ central node Fc.net (gene and CpG island) found various genes (TIAM1 \[[@ref021], [@ref022]\], CST7 \[[@ref025]\], TCEAL7 \[[@ref023], [@ref024]\] and RNF11 \[[@ref026]\]) that were not found by $L_{1} +$*Fc.net (gene)* and Enet. Likewise, *HLR* (${{L1}/2} + {L2}$) was unable to find these genes (CST7, TCEAL7 and RNF11) where these genes (TIAM1, CST7, TCEAL7 and RNF11) were found to be correlated with cancer in previous research. On one hand, all methods were able to find genes (MPO \[[@ref027], [@ref028]\], PTPRCAP \[[@ref029]\]); on the other hand, network penalty methods were able to find genes (CD248 \[[@ref031]\] and HOXB5 \[[@ref032]\]). In Table [4](#T4){ref-type="table"}, our algorithm $L_{1/2} +$ central node Fc.net (gene and CpG island) also found genes (CD200 \[[@ref030]\], SRD5A2L \[[@ref034]\], ENO1 \[[@ref033]\]) which have not been found in $L_{1} +$*Fc.net(gene)* and *Enet*. Additionally, gene CD200 and gene SRD5A2L also proved to be related to cancer. The $L_{1} +$ Fc.net and $L_{1/2} +$ central node Fc.net (gene and CpG island) algorithm, which has gene and island network information, also found gene (TNFAIP8 \[[@ref035]\]) which was not found by *Enet/HLR.*

4.. Conclusion {#S4}
==============

In biological molecular research, the analysis of DNA methylation may be a new practice for cancer research. In this paper, we used the enhanced $L_{1/2}$ penalized logistic regression model to extract divergently methylated CpG sites between healthy controls and ovarian cancer cases. We constructed the central node fully connected network which combines with genome information and CpG island information. We have advanced the corresponding coordinate descent algorithm suited for real DNA methylation data. This method not only has the $L_{1/2}$ penalty sparser than $L_{1}$, it also has more CpG sites relationship information. In real data, we used ovarian cancer samples with over 20,000 CpG sites. Even though the quantity of the selected CpG sites was less than previous methods, more corresponding CpG sites within genes selected were potentially associated with cancers. Therefore, by comparing to traditional methods, our method clearly achieved a higher predictive accuracy. Therefore, the proposed method offers an advanced tool to researchers in DNA methylation and can be a powerful tool for recognizing pathogenic CpG sites.
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